Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bio-Thera Secures FDA Approval For Sandoz-Partnered Bevacizumab Biosimilar

Avzivi Is The Second Bio-Thera Biosimilar – And The Second Chinese Biosimilar – To Secure FDA Approval

Executive Summary

Bio-Thera has received US Food and Drug Administration approval for its bevacizumab biosimilar, marking the second biosimilar drug researched, developed and manufactured by a Chinese pharmaceutical company to receive US approval.

You may also be interested in...



Bio-Thera Signs Latin American Partnership Deal For Two Undisclosed Biosimilars

The Chinese firm announced a new deal with Costa Rican company SteinCares that handed over the rights to two unnamed biosimilars in the region for an undisclosed sum.

Bio-Thera And Macter Partner On Bevacizumab

Bio-Thera Solutions has struck a deal with Macter International for rights to its BAT1706 biosimilar rival to Avastin (bevacizumab) in Pakistan and Afghanistan.

A Year Of Change: Sandoz Completes A Transformational 2023

An eventful 2023 for Sandoz saw multiple major deals and key launches, with the year culminating in the firm’s long-awaited spinoff from parent company Novartis in October.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel